Annovis Bio Inc. (NYSE: ANVS) has announced a collaboration with Weave Bio to support preparation of the planned New Drug Application (NDA) for buntanetap, its investigational oral therapy for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The move matters because it signals that Annovis is taking concrete steps to prepare a complex regulatory filing well ahead of key data, potentially accelerating the path to market for a drug that targets the underlying causes of neurodegeneration.
Under the collaboration, Annovis will use the Weave AI platform to draft, review, and manage NDA documents. However, the company's regulatory and clinical teams will retain responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA). This division of labor is important because it shows Annovis is leveraging artificial intelligence to improve efficiency while maintaining rigorous human oversight—a critical factor for regulatory credibility.
The timing of the collaboration is strategic. Annovis recently completed enrollment in its pivotal Phase 3 AD study, which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. The company aims to achieve database lock for the six-month treatment period in December 2026, followed by top-line symptomatic data in March 2027. By preparing most of the NDA before the data readout, Annovis could significantly shorten the time between data availability and submission, a key advantage in the competitive neurodegenerative disease space.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. If successful, buntanetap could offer a much-needed new approach for millions affected by AD and PD.
For investors and industry observers, the collaboration with Weave Bio underscores Annovis's commitment to operational efficiency and regulatory preparedness. It also highlights the growing role of AI in drug development, particularly in managing the immense documentation burden of an NDA. The company's ability to execute on this front could influence its timeline and, ultimately, its competitive positioning.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
This announcement was originally distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
